Mono-[ Approximately 2% of patients suffering from acute myocardial infarction (AMI) may be typically misdiagnosed on the basis of the presence of a characteristic chest pain or an altered electrocardiogram or biomarker pattern. Although this is only a small percentage of the total number of patients, the number of misdiagnosed AMI incidents is in the thousands because the total number of individuals suffering from AMI is very large (more than one million in the United States alone) (1). A quick diagnosis of AMI is important to devise a suitable treatment and increase the chances of a favorable outcome. The use of scintigraphic agents such as pyrophosphate labeled with radioactive technetium (